Improved diabetic control during oral sulfonylurea treatment in two children with permanent neonatal diabetes mellitus

Journal of Pediatric Endocrinology and Metabolism

Volumn 22, Issue 7, 2009, Pages 661-667

  Ting, Wei Hsin ^a   Huang, Chi Yu ^a,b   Lo, Fu Sung ^c   Lee, Hung Chang ^a,d   Lin, Chong G ^a   Guo, Wen Ling ^a   Lee, Yann Jinn ^a,d  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b NURSING AND MANAGEMENT COLLEGE   (Taiwan)

^c CHANG GUNG CHILDREN S HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

DEND syndrome; Glibenclamide; K+ ATP channel; KCNJ11; Kir6.2; Permanent neonatal diabetes; Sulfonylurea

Indexed keywords

C PEPTIDE; DIAMICRON MR; GLIBENCLAMIDE; GLICLAZIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; INWARDLY RECTIFYING POTASSIUM CHANNEL SUBUNIT KIR6.2; METHIONINE; SULFONYLUREA; UNCLASSIFIED DRUG; VALINE;

ADOLESCENT; ANTERIOR FONTANEL; ARTICLE; CASE REPORT; CENTRAL NERVOUS SYSTEM DEPRESSION; CHILD; CLINICAL FEATURE; DIABETES CONTROL; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DISEASE SEVERITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FETUS DISTRESS; FEVER; GENE MUTATION; GENETIC ANALYSIS; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE TEST; GLYCEMIC CONTROL; GROWTH; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; KETONURIA; LABORATORY TEST; MALE; MENTAL DEFICIENCY; MENTAL DEVELOPMENT; NEWBORN DISEASE; NUCLEOTIDE SEQUENCE; PERMANENT NEONATAL DIABETES MELLITUS; PHYSICAL EXAMINATION; PSYCHOMOTOR RETARDATION; SCHOOL CHILD; TACHYPNEA; TAIWAN; TREATMENT DURATION; TREATMENT OUTCOME; VERNER MORRISON SYNDROME;

EID: 69949118026     PISSN: 0334018X     EISSN: None     Source Type: Journal    
DOI: 10.1515/JPEM.2009.22.7.661     Document Type: Article

References (24)

1. Shield JP. Neonatal diabetes: new insights into aetiology and implications. Horm Res 2000; 53 (Suppl 1): 7-11. (Pubitemid 30481314)
2. Gloyn AL, Pearson ER, Antcliff JF, Proks P, Bruining GJ, Slingerland AS, et al. Activating mutations in the gene encoding the ATP-sensitive potassium-channel subunit Kir6.2 and permanent neonatal diabetes. N Engl J Med 2004; 350: 1838-1849. (Pubitemid 38917250)
3. Sagen JV, Raeder H, Hathout E, Shehadeh N, Gudmundsson K, Baevre H, et al. Permanent neonatal diabetes due to mutations in KCNJ11 encoding Kir6.2: patient characteristics and initial response to sulfonylurea therapy. Diabetes 2004; 53: 2713-2718. (Pubitemid 39299284)
4. Vaxillaire M, Populaire C, Busiah K, Cave H, Gloyn AL, Hattersley AT, et al. Kir6.2 mutations are a common cause of permanent neonatal diabetes in a large cohort of French patients. Diabetes 2004; 53: 2719-2722. (Pubitemid 39299285)
5. Hattersley AT, Ashcroft FM. Activating mutations in Kir6.2 and neonatal diabetes: new clinical syndromes, new scientific insights, and new therapy. Diabetes 2005;54:2503-2513. (Pubitemid 41233571)
6. Massa O, Iafusco D, D'Amato E, Gloyn AL, Hattersley AT, Pasquino B, et al. KCNJ11 activating mutations in Italian patients with permanent neonatal diabetes. Hum Mutat 2005; 25: 22-27. (Pubitemid 40075910)
7. Suzuki S, Makita Y, Mukai T, Matsuo K, Ueda O, Fujieda K. Molecular basis of neonatal diabetes in Japanese patients. J Clin Endocrinol Metab 2007; 92: 3979-3985. (Pubitemid 47607650)
8. Pearson ER, Flechtner I, Njolstad PR, Malecki MT, Flanagan SE, Larkin B, et al. Switching from insulin to oral sulfonylureas in patients with diabetes due to Ku-6.2 mutations. N Engl J Med 2006; 355: 467-477. (Pubitemid 44162274)
9. Ashcroft FM, Harrison DE, Ashcroft SJ. Glucose induces closure of single potassium channels in isolated rat pancreatic beta-cells. Nature 1984; 312: 446-448.
10. th, Namba N, Inazawa J, Gonzalez G, et al. Reconstitution of IKATP: an inward rectifier subunit plus the sulfonylurea receptor. Science 1995; 270: 1166-1170.
11. Babenko AP, Polak M, Cave H, Busiah K, Czernichow P, Scharfmann R, et al. Activating mutations in the ABCC8 gene in neonatal diabetes mellitus. N Engl J Med 2006; 355: 456-466. (Pubitemid 44162273)
12. Chan YM, Laffel LM. Transition from insulin to glyburide in a 4-month-old girl with neonatal diabetes mellitus caused by a mutation in KCNJ11. Pediatr Diabetes 2007; 8: 235-238.
13. Codner E, Flanagan SE, Ugarte F, Garcia H, Vidal T, Ellard S, et al. Sulfonylurea treatment in young children with neonatal diabetes: dealing with hyperglycemia, hypoglycemia, and sick days. Diabetes Care 2007; 30: e28-29. (Pubitemid 46684676)
14. Gurgel LC, Crispim F, Noffs MH, Belzunces E, Rahal MA, Moises RS. Sulfonylrea treatment in permanent neonatal diabetes due to G53D mutation in the KCNJ11 gene: improvement in glycemic control and neurological function. Diabetes Care 2007; 30: e108.
15. Kim MS, Kim SY, Kim GH, Yoo HW, Lee DW, Lee DY. Sulfonylurea therapy in two Korean patients with insulin-treated neonatal diabetes due to heterozygous mutations of the KCNJ11 gene encoding Kir6.2. J Korean Med Sci 2007; 22: 616-620.
16. Zung A, Glaser B, Nimri R, Zadik Z. Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2. J Clin Endocrinol Metab 2004; 89: 5504-5507. (Pubitemid 39518433)
17. Slingerland AS, Hattersley AT. Mutations in the Kir6.2 subunit of the KATP channel and permanent neonatal diabetes: new insights and new treatment. Ann Med 2005; 37: 186-195. (Pubitemid 40780436)
18. Flanagan SE, Edghill EL, Gloyn AL, Ellard S, Hattersley AT. Mutations in KCNJ11, which encodes Kir6.2, are a common cause of diabetes diagnosed in the first 6 months of life, with the phenotype determined by genotype. Diabetologia 2006; 49: 1190-1197.
19. Milner MJ, Kochian LV. Investigating heavy-metal hyperaccumulation using Thlaspi caerulescens as a model system. Ann Bot (Lond) 2008; 102: 3-13.
20. Moberg E, Kollind M, Lins PE, Adamson U. Estimation of blood-glucose variability in patients with insulin-dependent diabetes mellitus. Scand J Clin Lab Invest 1993; 53: 507-514. (Pubitemid 23244226)
21. Masia R, Koster JC, Tumini S, Chiarelli F, Colombo C, Nichols CG, et al. An ATP-binding mutation (G334D) in KCNJ11 is associated with a sulfonylurea-insensitive form of developmental delay, epilepsy, and neonatal diabetes. Diabetes 2007; 56: 328-336. (Pubitemid 46263069)
22. Monnier L, Mas E, Ginet C, Michel F, Villon L, Cristol JP, et al. Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes. JAMA 2006; 295: 1681-1687.
23. Kilpatrick ES, Rigby AS, Atkin SL. The effect of glucose variability on the risk of microvascular complications in type 1 diabetes. Diabetes Care 2006; 29: 1486-1490. (Pubitemid 44127568)
24. Gribble FM, Reimann F. Sulphonylurea action revisited: the post-cloning era. Diabetologia 2003; 46: 875-891. (Pubitemid 36961311)